X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-04-10 | SOPH | Van Well Daan | GC | S - Sale | $4.67 | -2,400 | 346,420 | -1% | -$11,201 | ||||||
| M | 2026-04-10 | SOPH | Xu Zhenyu | Chief Scientific Officer | S - Sale | $4.73 | -8,120 | 632,096 | -1% | -$38,374 | |||||
| M | 2026-04-10 | SOPH | Camblong Jurgi | CEO | S - Sale | $4.73 | -16,631 | 3,707,569 | 0% | -$78,668 | |||||
| M | 2026-04-10 | SOPH | Muken Ross | Pres | S - Sale | $4.73 | -8,129 | 685,232 | -1% | -$38,445 | |||||
| M | 2026-04-10 | SOPH | Menu Philippe | Chief Medical Officer | S - Sale | $4.73 | -8,125 | 268,596 | -3% | -$38,404 | |||||
| M | 2026-04-08 | SOPH | Camblong Jurgi | CEO | S - Sale | $4.80 | -4,750 | 3,724,200 | 0% | -$22,797 | |||||
| M | 2026-04-08 | SOPH | Muken Ross | Pres | S - Sale | $4.80 | -4,736 | 693,361 | -1% | -$22,727 | |||||
| M | 2026-04-08 | SOPH | Xu Zhenyu | Chief Scientific Officer | S - Sale | $4.80 | -4,736 | 640,216 | -1% | -$22,726 | |||||
| M | 2026-04-08 | SOPH | Menu Philippe | Chief Medical Officer | S - Sale | $4.80 | -4,731 | 276,721 | -2% | -$22,695 | |||||
2026-04-08 | SOPH | Valente Manuela | Chief People Officer | S - Sale | $4.85 | -3,824 | 215,451 | -2% | -$18,543 | ||||||
| M | 2026-04-08 | SOPH | Van Well Daan | GC | S - Sale | $4.80 | -4,849 | 348,820 | -1% | -$23,286 | |||||
2026-04-08 | SOPH | Cardoza George | CFO | S - Sale | $4.85 | -1,403 | 291,458 | 0% | -$6,801 | ||||||
| M | 2026-04-06 | SOPH | Menu Philippe | Chief Medical Officer | S - Sale | $4.86 | -5,100 | 281,452 | -2% | -$24,773 | |||||
2026-04-06 | SOPH | Puylaert Kevin | Chief Sales Officer | S - Sale | $4.86 | -624 | 148,230 | 0% | -$3,032 | ||||||
| M | 2026-04-06 | SOPH | Van Well Daan | GC | S - Sale | $4.86 | -5,105 | 353,669 | -1% | -$24,818 | |||||
| M | 2026-04-06 | SOPH | Muken Ross | Pres | S - Sale | $4.86 | -5,024 | 698,097 | -1% | -$24,405 | |||||
| M | 2026-04-06 | SOPH | Camblong Jurgi | CEO | S - Sale | $4.86 | -5,100 | 3,728,950 | 0% | -$24,769 | |||||
| M | 2026-04-06 | SOPH | Cardoza George | CFO | S - Sale | $4.86 | -4,933 | 292,861 | -2% | -$23,979 | |||||
| M | 2026-04-06 | SOPH | Valente Manuela | Chief People Officer | S - Sale | $4.86 | -4,973 | 219,275 | -2% | -$24,149 | |||||
| M | 2026-04-06 | SOPH | Xu Zhenyu | Chief Scientific Officer | S - Sale | $4.86 | -5,100 | 644,952 | -1% | -$24,780 | |||||
| M | 2026-04-06 | SOPH | Verma Abhimanyu | CTO | S - Sale | $4.86 | -3,549 | 204,400 | -2% | -$17,256 | |||||
2026-03-31 | SOPH | Puylaert Kevin | Chief Sales Officer | S - Sale | $4.71 | -3 | 92,383 | 0% | -$14 | ||||||
2026-03-19 | SOPH | Van Well Daan | GC | S - Sale | $4.79 | -684 | 261,238 | 0% | -$3,274 | ||||||
2026-03-19 | SOPH | Camblong Jurgi | CEO | S - Sale | $4.77 | -4,486 | 3,302,839 | 0% | -$21,410 | ||||||
2026-03-19 | SOPH | Menu Philippe | Chief Medical Officer | S - Sale | $4.79 | -608 | 173,616 | 0% | -$2,913 | ||||||
2026-03-19 | SOPH | Xu Zhenyu | Chief Scientific Officer | S - Sale | $4.78 | -608 | 537,116 | 0% | -$2,907 | ||||||
2026-03-19 | SOPH | Valente Manuela | Chief People Officer | S - Sale | $4.79 | -380 | 152,379 | 0% | -$1,818 | ||||||
2026-03-19 | SOPH | Muken Ross | Pres | S - Sale | $4.79 | -1,183 | 271,910 | 0% | -$5,671 | ||||||
2026-03-19 | SOPH | Puylaert Kevin | Chief Sales Officer | S - Sale | $4.76 | -33 | 92,386 | 0% | -$157 | ||||||
2026-03-19 | SOPH | Cardoza George | CFO | S - Sale | $4.79 | -774 | 184,858 | 0% | -$3,705 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |